RBM17 and acute myeloid leukemia: In keeping with the increased level of mRNA, RBM17 protein is 1.68 fold higher in the LSC-enriched primitive cell subsets (CD34+) of primary AML patient samples (Supplementary Table 1) compared to the more committed cell subsets (CD34-) (Fig. 1e, Supplementary Fig. 1d-e), providing further support that elevated RBM17 preferentially marks the primitive compartments of human AML.